lademirsen (SAR339375)

Phase 2Small molecule

Sanofi

lademirsen (SAR339375) is one of 10 small molecule programs targeting Alport syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alport SyndromeActive, not recruiting

Alport SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Alport Syndrome

#DrugCompanyPhaseTrials

Lescol

Glucophage

1 3

Reata

Biogen

Phase 3

1 4

Farxiga

AstraZeneca

Preclinical

1 5

Zemplar

AbbVie

Preclinical

1 6

ELX-02

EEloxx Pharmaceuticals, Inc.

Phase 2

1 7

Setanaxib

CCalliditas Therapeutics Suisse SA

Phase 2

1 8

Vonafexor

EEnyo Pharma

Phase 2

1 9

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 10

lademirsen (SAR339375)

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alport syndrome1 trial

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Terminated· Sanofi logo

Sanofi·Phase 2·NCT02855268·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for lademirsen (SAR339375). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — lademirsen (SAR339375) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for lademirsen (SAR339375). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

lademirsen (SAR339375)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alport syndrome1 trial

References

Drug Info

Quick Facts

Related News